Mardi Dier joined Portola in August 2006 as senior vice president and chief financial officer and has served as executive vice president and chief financial officer since November 2013. Ms. Dier is responsible for leading the corporate finance, accounting, information technology, global supply chain, investor relations and corporate communications functions. Ms. Dier brings to Portola nearly 20 years’ experience in the life sciences industry. During her tenure at Portola, she has successfully led a series of private, public and alternative financings. Previously, she served as vice president of investor relations at Chiron Corporation from 2003 until its acquisition by Novartis Pharmaceuticals in April 2006. Prior to joining Chiron, she served as a director in the West Coast investment banking practice at Prudential Securities, where she focused on client development, equity underwriting, and mergers and acquisitions for biotechnology and other life sciences companies. Ms. Dier began her finance career in the audit department of KPMG Peat Marwick.
She holds a B.S. in biology from Stanford University and an M.B.A. from the Anderson School at the University of California, Los Angeles. Ms. Dier is a member of the board of directors of Adamas Pharmaceuticals, Inc., a company focused on chronic neurological diseases.